Skip to main content
SpringerLink
Log in

A phase II trial of m-AMSA in head and neck cancer

  • Original Articles
  • m-AMSA Head and Neck Cancer
  • Published:
Cancer Chemotherapy and Pharmacology Aims and scope Submit manuscript

Summary

Twenty patients with advanced epidermoid carcinoma from primary sites in the head and neck region received adequate trials of therapy with m-AMSA, at starting doses of 90 or 120 mg/m2. Despite the good median performance status of the group (median 80) and the fact that 50% of the patients had received no prior chemotherapy, only one minor response was achieved. AMSA appears to have no useful activity in this dose and schedule in patients with epidermoid head and neck cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Ahmann E, Meyskens F, Jones S, Durie B, Alberto D, Salmon S (1980) A broad phase II trial of AMSA with in vitro stem cell culture drug sensitivity correlation. Proc Am Soc Clin Oncol 21: 369

    Google Scholar 

  2. Cain BF, Atwell GJ (1974) The experimental antitumor properties of three congeners of the acridylmethanesulphonanilide (AMSA) series. Eur J Cancer 10: 539

    Google Scholar 

  3. Hansen H, Arlin Z, Fried J, Yen A, Clarkson B (1980) m-AMSA: effects on neoplastic cellular proliferation in vivo in human leukemia and lymphoma. Proc Am Assoc Cancer Res 21: 179

    Google Scholar 

  4. Legha SS, Gutterman JV, Hall SW, Benjamin RS, Burgess MA, Valdivieso M, Bodey GP (1978) Phase I clinical investigation of 4′-(9-acridinylamino)methanesulfon-m-anisidide (NSC 249992), a new acridine derivative. Cancer Res 38: 3712

    Google Scholar 

  5. Legha SS, Blumenschein GR, Buzdar AU, Hortobagyi GN, Bodey GP (1980) Phase II study of 4′-(9-acridinylamino)methanesulfon-m-anisidide (AMSA) in metastatic breast cancer. Cancer Treat Rep 63: 1961

    Google Scholar 

  6. Sordillo P, Magill GB (to be published) Phase II evaluation of m-AMSA in patients with advanced sarcoma. Cancer Treat Rep

  7. Von Hoff DD, Howser D, Gormley P, Bender RA, Glaubiger D, Levine AS, Young RC (1978) Phase I study of methanesulfonamide, N-(4-(9-acridinylamino)-3-methoxyphenyl)-(m-AMSA), using a single-dose schedule. Cancer Treat Rep 62: 1421

    Google Scholar 

  8. Woodcock TM, Schneider RJ, Young CW (1980) Phase I evaluation of 4′-(9-acridinylamino)methanesulfon-m-anisidide (AMSA) by a weekly intravenous dose schedule. Cancer Treat Rep 64: 53

    Google Scholar 

Download references

Author information

Author notes

  1. Arlene A. Forastiere

    Present address: Baltimore Cancer Research Program, Division of Cancer Treatment, National Cancer Institute, 22 S. Greene Street, 21201, Baltimore, MD, USA

Authors and Affiliations

  1. The Solid Tumor and Developmental Chemotherapy Services, Department of Medicine, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, 10021, New York, NY, USA

    Arlene A. Forastiere, Charles W. Young & Robert E. Wittes

Authors
  1. Arlene A. Forastiere
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Charles W. Young
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Robert E. Wittes
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Forastiere, A.A., Young, C.W. & Wittes, R.E. A phase II trial of m-AMSA in head and neck cancer. Cancer Chemother. Pharmacol. 6, 145–146 (1981). https://doi.org/10.1007/BF00262333

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00262333

Keywords

Search

Navigation